Evaluating the efficacy of different tribendimidine combinations against intestinal worms (soil-transmitted helminths)
| ISRCTN | ISRCTN14373201 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN14373201 |
| Secondary identifying numbers | N/A |
- Submission date
- 07/07/2016
- Registration date
- 19/07/2016
- Last edited
- 30/08/2023
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Infections and Infestations
Plain English summary of protocol
Background and study aims
Soil-transmitted helminthes, such as hookworm and whipworm (intestinal worms that are spread via contaminated soil) are a serious health concern in South-East Asia, Africa and South America, especially in school-age children. The standard treatment, recommended by the World Health Organization (WHO), is use of preventive chemotherapy drugs albendazole and mebendazole. However, overuse of these drugs increases the chance that the worms will become resistant to their effects. To be prepared for this situation new drugs have to be identified to replace the old ones. Tribendimidine (a general anti-worms drug) has been shown to be effective in the treatment of soil-transmitted helminthes (STH) and could act as albendazole/mebendazole replacement in case of resistance. Additionally, none of the current drugs used to treat STH are particularly effective against whipworm, except the new drug oxantel pamoate. The aim of this study is to investigate the most effective combination of albendazole plus oxantel pamaote for the treatment of STH infections.
Who can participate?
Patients aged between 15 and 18 years old with hookworm eggs in their stool, who are otherwise healthy.
What does the study involve?
Participants are randomly allocated to one of four groups who receive a single dose of medication on day one of the study. Those in the first group receive a dose of tribendimidine (400mg) plus oxantel pamoate (25mg/kg); those in the second group receive a dose of tribendimidine (400mg) plus ivermectin (200µg/kg); those in the third group receive a dose of tribendimidine (400mg) plus placebo (dummy pill); and those in the fourth groups receive a dose of albendazole (400mg) plus oxantel pamoate (25mg/kg). At the start of the study and then after 14-21 days, participants provide stool samples on two consecutive days so that the amount of STH eggs can be counted to find out the efficacy of the medications.
What are the possible benefits and risks of participating?
All participants enrolled in the study will benefit from a treatment against STHs. Very few negative side effects have been reported for the medications used in this study, however there is a small risk of abdominal (tummy) cramps, fever, nausea and headache, and vertigo (spinning sensation).
Where is the study run from?
1. Public Health Laboratory Ivo de Carneri (Tanzania)
2. Centre Suisse de Recherches Scientifiques en Côte d'Ivoire (Côte d'Ivoire)
When is the study starting and how long is it expected to run for?
February 2015 to May 2017
Who is funding the study?
Swiss National Science Foundation (Switzerland)
Who is the main contact?
Professor Jennifer Keiser
jennifer.keiser@unibas.ch
Contact information
Scientific
Swiss Tropical ad Public Health Institute
Socinstrasse 57
Basel
4005
Switzerland
Study information
| Study design | Single-blinded randomized interventional study |
|---|---|
| Primary study design | Interventional |
| Secondary study design | Randomised controlled trial |
| Study setting(s) | Community |
| Study type | Treatment |
| Participant information sheet | Not available in web format, please use the contact details below to request a patient information sheet |
| Scientific title | Efficacy and safety of tribendimidine plus oxantel, tribendimidine plus ivermectin, albendazole plus oxantel pamoate and tribendimidine alone against hookworm and concomitant soil-transmitted helminth infections: a randomised controlled multi-country trial |
| Study acronym | Tricombi |
| Study objectives | The aim of this study is to provide evidence that tribendimidine in combination with oxantel pamoate or ivermectin could serve as an alternative to the currently most efficacious combination albendazole-oxantel against soil-transmitted helminth infections in Côte d’Ivoire and Tanzania. |
| Ethics approval(s) | 1. Ethikkommission Nordwest-und Zentralschweiz EKNZ, 25/06/2015, ref: EKNZ UBE 15/35 (Switzerland) 2. Zanzibar Medical Research and Ethics Committee ZAMREC, 11/07/2016, ref: ZAMREC /0001/July/016 (Tanzania) 3. Comité National d'Ethique pour la Recherche CNER, 09/09/2016, ref : 083/MSHP/CNER-kp |
| Health condition(s) or problem(s) studied | Hookworm infection |
| Intervention | Study participants eligible for treatment will be randomly assigned to one of the four treatment arms using a computer-generated stratified block randomization code. The random allocation sequence with varying random blocks of four or eight will be provided by a statistician. Group 1: One single dose of tribendimidine (400mg) plus oxantel pamoate (25mg/kg) Group 2: One single dose of tribendimidine (400mg) plus ivermectin (200µg/kg) Group 3: One single dose of tribendimidine (400mg) plus placebo Group 4: One single dose of albendazole (400mg) plus oxantel pamoate (25mg/kg) At follow-up (after 14-21 days) participants will be asked to provide a second time two stool samples on two consecutive days. |
| Intervention type | Drug |
| Pharmaceutical study type(s) | Not Applicable |
| Phase | Not Applicable |
| Drug / device / biological / vaccine name(s) | 1. Tribendimidine 2. Oxantel pamoate 3. Ivermectin 4. Albendazole |
| Primary outcome measure | Egg-reduction rates against hookworm are measured calculating the mean reduction in egg-counts at follow-up (after 14-21 days) compared to baseline (based on quadruplicated Kato-Katz thick smears). |
| Secondary outcome measures | 1. Cure rate (CR) against hookworm is the percentage of children egg negative calculated at follow-up (14-21 days post treatment) based on a quadruplicated Kato-Katz thick smear 2. Cure rate (CR) and egg-reduction rate (ERR) against A. lumbricoides and T. trichiura are egg free children at follow-up (14-21 days post treatment based on a quadruplicated Kato-Katz thick smear) or the mean reduction in egg-counts at follow-up (after 14-21 days) compared to baseline (based on quadruplicated Kato-Katz thick smear) 3. Pharmacokinetic parameters are determined based on concentration of the different drugs measured 4. Safety is measured based on number of children reporting adverse events at the time points 3 and 24 hours post treatment using a standardized questionnaire |
| Overall study start date | 01/02/2015 |
| Completion date | 01/05/2017 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Mixed |
| Sex | Both |
| Target number of participants | 640 (400 in Tanzania, 240 in Côte d’Ivoire) |
| Key inclusion criteria | 1. Written informed consent signed by parents and/or legal guardian; and assent by children 2. Able and willing to be examined by a study physician at the beginning of the study 3. Able and willing to provide two stool samples at the beginning (baseline) and approximately three weeks after treatment (follow-up) 4. Positive for hookworm eggs in the stool 5. Absence of major systemic illnesses (e.g. diabetes, anemia) as assessed by a medical doctor, upon initial clinical assessment 6. No known or reported history of chronical illness as cancer, diabetes, chronic heart, liver or renal disease 7. No recent anthelminthic treatment (within past 4 weeks) 8. No known allergy to study medications (e.g. albendazole, mebendazole) 9. Aged 15-18 years |
| Key exclusion criteria | 1. No written informed consent by parents and/or legal guardian and assent for children 2. Presence of major systemic illnesses (e.g. diabetes, anemia) as assessed by a medical doctor, upon initial clinical assessment 3. History of acute or severe chronic disease 4. Recent use of anthelminthic drug (within past 4 weeks) 5. Attending other clinical trials during the study 6. Negative diagnostic result for hookworm eggs in the stool |
| Date of first enrolment | 25/07/2016 |
| Date of final enrolment | 02/12/2016 |
Locations
Countries of recruitment
- Côte d'Ivoire
- Tanzania
Study participating centres
Tanzania
Côte d'Ivoire
Sponsor information
University/education
Socinstrasse 57
Basel
4005
Switzerland
| Website | www.swisstph.ch |
|---|---|
"ROR" |
https://ror.org/03adhka07 |
Funders
Funder type
Research organisation
No information available
Results and Publications
| Intention to publish date | 01/05/2017 |
|---|---|
| Individual participant data (IPD) Intention to share | No |
| IPD sharing plan summary | Stored in repository |
| Publication and dissemination plan | The final results of this study will be published in a scientific journal and presented at scientific conferences. All results from this investigation are considered confidential and shall not be made available to any third part by any member of the investigating team before publication |
| IPD sharing plan |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Results article | results | 01/11/2017 | Yes | No | |
| Other publications | diagnostic comparison conducted in the framework of the clinical trial based exclusively on samples collected in Tanzania | 04/06/2018 | 30/08/2023 | Yes | No |
Editorial Notes
30/08/2023: Publication reference added.
05/12/2017: internal review.
05/09/2017: Publication reference added.
04/04/2017: The dose of tribendimidine used in this study has been updated fromk 200mg to 400mg - this has been updated in the interventions section and plain English summary. In addition, the approval information of the third ethics approval has been added.
